SCP
IART icon

Syntal Capital Partners’s Integra LifeSciences IART Stock Holding History

Syntal Capital Partners’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,694
Closed -$317 – 117
2016
Q3 		$317 Buy
+7,694
New +$322K 0.19% 48

Other funds holding IART

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Syntal Capital Partners's IART Position: Q4 2016 in Review

Syntal Capital Partners sold out of Integra LifeSciences (IART) in Q4 2016, closing a stake of 7,694 shares — an estimated $317 sold.

Syntal Capital Partners first reported a position in IART in Q3 2016 and held it in 1 quarter. The position peaked at $317 in Q3 2016. 223 funds tracked by Wall St. Rank hold IART as of Q4 2016.

  • Syntal Capital Partners reported no remaining Integra LifeSciences position as of Q4 2016 after selling out during the quarter.
  • Syntal Capital Partners sold 7,694 Integra LifeSciences shares in Q4 2016, an estimated $317.
  • Syntal Capital Partners first reported a position in Integra LifeSciences in Q3 2016 and held it in 1 quarter.
  • Syntal Capital Partners's Integra LifeSciences position peaked at $317 in Q3 2016.
  • 223 funds tracked by Wall St. Rank held Integra LifeSciences as of Q4 2016.

Based on Syntal Capital Partners's 13F filing for Q4 2016, filed 9 Feb 2017.